Author Archive: Celia Economides

Celia was a Manager of Investor Relations & Business Development at BIO.

Latest Posts

Provectus starts compassionate use program for PV-10

Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) expanded its compassionate use program for PV-10, making the agent, which is being developed as a therapeutic agent for a broad spectrum of cancers, available for select cancer patients in the United States. The program is already in progress in Australia, where it was initiated in June 2009. The program for PV-10 is being implemented under the FDA’s guidelines covering compassionate use of an investigational new drug. Read the release.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Novavax gets NIH grant

Novavax, Inc. (NASDAQ:NVAX) has received a Small Business and Innovation Research grant from the National Institute of Allergy and Infectious Diseases. The grant will support a segment of the Company’s preclinical research program for the respiratory syncytial virus (RSV) particle-based vaccine. As previously announced, Novavax has an RSV vaccine candidate in preclinical development, which is directed against a protein on the surface of the virus, the “F” or “fusion” protein. The grant, valued at approximately Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Canadian patent strengthens IP for Allon’s 2nd technology platform

Allon Therapeutics Inc. (TSX: NPC), announced today that the intellectual property underlying its activity-dependent neurotrophic factor (ADNF) technology platform has been strengthened by the issuance of a Canadian patent covering the chemical composition of the Company’s preclinical-stage peptide AL-209 and its use in protecting against Alzheimer’s disease and other degenerative diseases. The Company said AL-209 has demonstrated highly potent neuroprotective activity in preclinical studies where it has been shown to block the effect of toxic Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Positive Phase 2 results for TOPICA’s luliconazole

TOPICA Pharmaceuticals had positive results from its Phase 2 clinical study evaluating luliconazole, a topical antifungal agent, in patients with tinea pedis (athlete’s foot). The study assessed the effectiveness of luliconazole cream applied once daily for 14 days compared with once daily for 28 days.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

WILEX receives approval for Phase I trial

WILEX AG (ISIN DE0006614720 / Frankfurt Stock Exchange / Prime Standard) announced that the German Federal Institute for Drugs and Medical Devices approved the Phase I trial with the MEK inhibitor WX-554. The trial is a first-in-man-trial in healthy volunteers and will be conducted at a single site in Germany. With the first dose in man, the second milestone payment of EUR 5 million agreed in the strategic alliance with UCB Pharma S.A. will become Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,